🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11,276 results for “Te” Clear

  1. Rebamipide

    Otsuka Beijing Research Institute

    Stomach Ulcer

    approved small molecule completed

    1 trial
  2. Recaticimab

    The First People's Hospital of Lianyungang

    STEMI - ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial
  3. Recigarum 1,5 mg comprimidos recubiertos con película EFG

    The George Institute

    Active smokers

    approved small molecule active

    1 trial
  4. Recombinant FSH (follitropin alpha)

    United Therapeutics Europe Ltd

    Ovulation Induction

    approved small molecule completed

    1 trial
  5. Recombinant Protein-Free Factor VIII (rAHF-PFM)

    Takeda

    Hemophilia A

    approved small molecule completed

    1 trial
  6. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    ST-segment Elevation Myocardial Infarction (STEMI)

    approved small molecule completed

    1 trial
  7. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule completed

    1 trial
  8. Recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules)

    United Therapeutics Europe Ltd

    Diarrhea

    approved mab active

    1 trial
  9. Regadenoson

    Aspire Biopharma Holdings

    Coronary Artery Disease

    approved small molecule completed

    1 trial
  10. Regiocit solution pour hémofiltration

    Pari Pharma GmbH

    Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay.

    approved small molecule active

    1 trial
  11. Rematazolam Besylate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Emergence Agitation

    approved small molecule active

    1 trial
  12. Remimazolam Besylate for Injection

    The First People's Hospital of Lianyungang

    Thoracic Surgery

    approved small molecule active

    1 trial
  13. Remodulin

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    approved small molecule completed

    1 trial
  14. Remsima 100 mg powder for concentrate for solution for infusion

    Disc Medicine

    Crohn's Disease

    approved small molecule active

    1 trial
  15. Renin-angiotensin system blockers

    Hospital Authority, Hong Kong

    Diabetes

    approved small molecule active

    1 trial
  16. Repatha 140 mg solution for injection in pre-filled pen

    Pari Pharma GmbH

    acute myocardial infarction

    approved small molecule active

    1 trial
  17. Rescue Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Neovascular Polypoidal Choroidal Vasculopathy

    approved small molecule active

    1 trial
  18. Reslizumab

    Teva Pharma GmbH

    Asthma; Eosinophilic

    approved mab completed

    1 trial
  19. Reslizumab

    Teva Pharma GmbH

    Asthma

    approved small molecule active

    5 trials
  20. Resveratrol

    The First People's Hospital of Lianyungang

    Pancreatitis, Acute

    approved small molecule active

    1 trial
  21. Revefenacin

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease

    approved small molecule completed

    1 trial
  22. Reyanning mixture

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Tonsillitis

    approved small molecule active

    1 trial
  23. Rifaldin 300 mg cápsulas, Rimactán 300 mg cápsulas duras, Cemidón 300 B6, RIFAPENTINE

    The George Institute

    Latent tuberculosis infection in patients with end-stage kidney disease.

    approved small molecule active

    1 trial
  24. Rifaximin

    United Therapeutics Europe Ltd

    Nonalcoholic Fatty Liver Disease

    approved small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources